Mylan Nears $30M Deal In SEC EpiPen Probe; CEO To Retire
Mylan NV has reached a tentative agreement to pay $30 million to resolve the U.S. Securities and Exchange Commission's probe into allegations that the pharmaceutical company ripped off the government by...To view the full article, register now.
Already a subscriber? Click here to view full article